Clinical Trial Update: NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial update of NPI-0052 (marizomib) and vorinostat in patients with non-small cell lung cancer, pancreatic cancer, melanoma, lymphoma, and multiple mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Melanoma
• Multiple Myeloma
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• Vorinostat (vorinostat)
• marizomib (NPI-0052) (marizomib)

Snippet

Sponsor: Celgene | Conditions: Non-Small Cell Lung Cancer, Pancreatic Cancer | Phase 1 | Status: COMPLETED